Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Reeling from PD-1 slapdown, Incyte stirs concerns with side effects of oral PD-L1 although drug is also ''clearly active''
12:18pm, Monday, 15'th Nov 2021 Endpoints News
The rejection of its PD-1 inhibitor, retifanlimab, was never going to be the end of Incytes checkpoint story. Not only was the biotech holding out hope of changing the FDAs mind and testing the cancer drug in multiple combinations, it also lined up a trio of oral PD-L1 candidates as
Incyte's Increase In Jakafi's Sales Guidance Implies 29% Upside In The Valuation
11:36am, Tuesday, 09'th Nov 2021
Incyte's Increase In Jakafi's Sales Guidance Implies 29% Upside In The Valuation
Incyte Corporation (INCY) CEO Herve Hoppenot on Q3 2021 results - Earnings Call Transcript
11:12am, Tuesday, 02'nd Nov 2021
Incyte Corporation (INCY) CEO Herve Hoppenot on Q3 2021 results - Earnings Call Transcript
Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow
10:43am, Tuesday, 02'nd Nov 2021
Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.
Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas
07:27pm, Monday, 01'st Nov 2021
The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), and mant
Should You Buy Incyte Corporation (INCY) Ahead of Earnings?
11:28am, Friday, 29'th Oct 2021
Incyte Corporation (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?
12:13pm, Thursday, 28'th Oct 2021
Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
10:00am, Wednesday, 27'th Oct 2021
It's much too early to count these companies out.
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
04:40pm, Tuesday, 26'th Oct 2021
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
01:25pm, Tuesday, 26'th Oct 2021
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
There's Money to Be Made With Vertex, Viatris, Incyte and Biogen
11:54am, Sunday, 24'th Oct 2021
A screening of healthcare stocks in the S&P 500 reveals that investors may find plenty of upside in three members of the index, according to an article in Barron's. The analysis showed that Vertex Pha
Incyte's (INCY) Going Gets Rough Despite Recent Approvals
10:43am, Wednesday, 13'th Oct 2021
Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
05:15am, Saturday, 02'nd Oct 2021
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADVCongress--Incyte Announces Full Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients with Vitiligo
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
02:15pm, Friday, 01'st Oct 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NM
INDIANAPOLIS, Sept. 30, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), wh
